Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ABIOMED, Inc. - Common Stock (NQ: ABMD )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 21, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ABIOMED, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
From Abiomed, Inc.
Via Business Wire
Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
From Abiomed, Inc.
Via Business Wire
MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
From Abiomed, Inc.
Via Business Wire
FDA Approves Abiomed's Impella Low Profile Sheath
Via Benzinga
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
From Abiomed, Inc.
Via Business Wire
U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
From Abiomed, Inc.
Via Business Wire
Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
From Abiomed, Inc.
Via Business Wire
Abiomed's Impella Shows Heart Function, Symptom Improvements For High-Risk PCI Patients
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
Abiomed: Q1 Earnings Insights
  Abiomed (NASDAQ:ABMD) reported its Q1 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Abiomed Q4 Earnings
Abiomed (NASDAQ:ABMD) reported its Q4 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
From Abiomed, Inc.
Via Business Wire
Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
From Abiomed, Inc.
Via Business Wire
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
From Abiomed, Inc.
Via Business Wire
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
From Abiomed, Inc.
Via Business Wire
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
From Abiomed, Inc.
Via Business Wire
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
From Abiomed
Via Business Wire
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
From Abiomed, Inc.
Via Business Wire
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Quant Ratings Updated on 97 Stocks
Over the weekend, I revised my Portfolio Grader recommendations for 97 blue-chip stocks, and many of them were in the tech industry 
Via InvestorPlace
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
From Abiomed, Inc.
Via Business Wire
Quant Ratings Updated on 85 Stocks
In today’s Market360, I have included a list of 10 stocks that were upgraded from a Hold to a Buy over the holiday weekend. 
Via InvestorPlace
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
From Abiomed, Inc.
Via Business Wire
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
From Abiomed
Via Business Wire
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
From Abiomed, Inc.
Via Business Wire
A Preview Of Abiomed's Earnings
Abiomed (NASDAQ:ABMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Abiomed will report... 
Via Benzinga
World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump
From Abiomed
Via Business Wire
Markets Rise Despite Another New 2-Year High For US 10-Year Treasury Note
U.S. indices traded higher Tuesday on continued volatility as traders assess Fed policy outlook, rising Treasury yields and quarterly earnings reports. Investors continued to... 
Via Benzinga
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.